Literature DB >> 27401825

Neurotoxicity in Sri Lankan Russell's Viper (Daboia russelii) Envenoming is Primarily due to U1-viperitoxin-Dr1a, a Pre-Synaptic Neurotoxin.

Anjana Silva1,2, Sanjaya Kuruppu3,4, Iekhsan Othman5, Robert J A Goode4, Wayne C Hodgson3, Geoffrey K Isbister3,6.   

Abstract

Russell's vipers are snakes of major medical importance in Asia. Russell's viper (Daboia russelii) envenoming in Sri Lanka and South India leads to a unique, mild neuromuscular paralysis, not seen in other parts of the world where the snake is found. This study aimed to identify and pharmacologically characterise the major neurotoxic components of Sri Lankan Russell's viper venom. Venom was fractionated using size exclusion chromatography and reverse-phase high-performance liquid chromatography (RP-HPLC). In vitro neurotoxicities of the venoms, fractions and isolated toxins were measured using chick biventer and rat hemidiaphragm preparations. A phospholipase A2 (PLA2) toxin, U1-viperitoxin-Dr1a (13.6 kDa), which constitutes 19.2 % of the crude venom, was isolated and purified using HPLC. U1-viperitoxin-Dr1a produced concentration-dependent in vitro neurotoxicity abolishing indirect twitches in the chick biventer nerve-muscle preparation, with a t 90 of 55 ± 7 min only at 1 μM. The toxin did not abolish responses to acetylcholine and carbachol indicating pre-synaptic neurotoxicity. Venom, in the absence of U1-viperitoxin-Dr1a, did not induce in vitro neurotoxicity. Indian polyvalent antivenom, at the recommended concentration, only partially prevented the neurotoxic effects of U1-viperitoxin-Dr1a. Liquid chromatography mass spectrometry analysis confirmed that U1-viperitoxin-Dr1a was the basic S-type PLA2 toxin previously identified from this venom (NCBI-GI: 298351762; SwissProt: P86368). The present study demonstrates that neurotoxicity following Sri Lankan Russell's viper envenoming is primarily due to the pre-synaptic neurotoxin U1-viperitoxin-Dr1a. Mild neurotoxicity observed in severely envenomed Sri Lankan Russell's viper bites is most likely due to the low potency of U1-viperitoxin-Dr1a, despite its high relative abundance in the venom.

Entities:  

Keywords:  Neurotoxicity; Phospholipase A2; Pre-synaptic; Russell’s viper

Mesh:

Substances:

Year:  2016        PMID: 27401825     DOI: 10.1007/s12640-016-9650-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  27 in total

1.  A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia Russelii Russelii): a preliminary dose-finding and pharmacokinetic study.

Authors:  C A Ariaratnam; W P Meyer; G Perera; M Eddleston; S A Kuleratne; W Attapattu; R Sheriff; A M Richards; R D Theakston; D A Warrell
Journal:  Am J Trop Med Hyg       Date:  1999-08       Impact factor: 2.345

2.  Comparative characterisation of Russell's viper (Daboia/Vipera russelli) venoms from different regions of the Indian peninsula.

Authors:  N B Prasad; B Uma; S K Bhatt; V T Gowda
Journal:  Biochim Biophys Acta       Date:  1999-08-05

3.  A rational nomenclature for naming peptide toxins from spiders and other venomous animals.

Authors:  Glenn F King; Margaret C Gentz; Pierre Escoubas; Graham M Nicholson
Journal:  Toxicon       Date:  2008-06-13       Impact factor: 3.033

4.  Dissociation of catalytic activity and neurotoxicity of a basic phospholipase A2 from Russell's viper (Vipera russelli) venom.

Authors:  G P Jayanthi; S Kasturi; T V Gowda
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

5.  Neurotoxicity in Russell's viper (Daboia russelii) envenoming in Sri Lanka: a clinical and neurophysiological study.

Authors:  Anjana Silva; Kalana Maduwage; Michael Sedgwick; Senaka Pilapitiya; Prasanna Weerawansa; Niroshana J Dahanayaka; Nicholas A Buckley; Sisira Siribaddana; Geoffrey K Isbister
Journal:  Clin Toxicol (Phila)       Date:  2016-02-29       Impact factor: 4.467

6.  Purification and characterization of a major phospholipase A2 from Russell's viper (Vipera russelli) venom.

Authors:  S Kasturi; T V Gowda
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

7.  Purification, characterization, and chemical modification of neurotoxic peptide from Daboia russelii snake venom of India.

Authors:  Madhukumar Venkatesh; Nijaguna Prasad; Tej Sing; Veerabasappa Gowda
Journal:  J Biochem Mol Toxicol       Date:  2013-04-29       Impact factor: 3.642

8.  Biochemical composition, lethality and pathophysiology of venom from two cobras-- Naja naja and N. kaouthia.

Authors:  A K Mukherjee; C R Maity
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2002-02       Impact factor: 2.231

9.  Bites by Russell's vipers (Daboia russelii siamensis) in Myanmar: effect of the snake's length and recent feeding on venom antigenaemia and severity of envenoming.

Authors:  D A Warrell
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Nov-Dec       Impact factor: 2.184

10.  Efficacy of Indian polyvalent snake antivenoms against Sri Lankan snake venoms: lethality studies or clinically focussed in vitro studies.

Authors:  Kalana Maduwage; Anjana Silva; Margaret A O'Leary; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

View more
  23 in total

1.  Defining the role of post-synaptic α-neurotoxins in paralysis due to snake envenoming in humans.

Authors:  Anjana Silva; Ben Cristofori-Armstrong; Lachlan D Rash; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Cell Mol Life Sci       Date:  2018-08-01       Impact factor: 9.261

2.  Diverse and Dynamic Alpha-Neurotoxicity Within Venoms from the Palearctic Viperid Snake Clade of Daboia, Macrovipera, Montivipera, and Vipera.

Authors:  Abhinandan Chowdhury; Christina N Zdenek; Bryan G Fry
Journal:  Neurotox Res       Date:  2022-10-04       Impact factor: 3.978

3.  Clinical and Pharmacological Investigation of Myotoxicity in Sri Lankan Russell's Viper (Daboia russelii) Envenoming.

Authors:  Anjana Silva; Christopher Johnston; Sanjaya Kuruppu; Daniela Kneisz; Kalana Maduwage; Oded Kleifeld; A Ian Smith; Sisira Siribaddana; Nicholas A Buckley; Wayne C Hodgson; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2016-12-02

4.  Multipurpose HTS Coagulation Analysis: Assay Development and Assessment of Coagulopathic Snake Venoms.

Authors: 
Journal:  Toxins (Basel)       Date:  2017-11-25       Impact factor: 4.546

5.  Dacin, one metalloproteinase from Deinagkistrodon acutus venom inhibiting contraction of mouse ileum muscle.

Authors:  Bin Zhou; Gang Liu; Qiyi He; Bo Li; Xiaodong Yu
Journal:  BMC Biochem       Date:  2017-07-12       Impact factor: 4.059

Review 6.  Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.

Authors:  Julien Slagboom; Jeroen Kool; Robert A Harrison; Nicholas R Casewell
Journal:  Br J Haematol       Date:  2017-02-24       Impact factor: 6.998

Review 7.  Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming.

Authors:  Anjana Silva; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2017-04-19       Impact factor: 4.546

8.  Cross-Neutralisation of In Vitro Neurotoxicity of Asian and Australian Snake Neurotoxins and Venoms by Different Antivenoms.

Authors:  Anjana Silva; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2016-10-18       Impact factor: 4.546

9.  The Cardiovascular and Neurotoxic Effects of the  Venoms of Six Bony and Cartilaginous Fish Species.

Authors:  Han Han; Kate Baumann; Nicholas R Casewell; Syed A Ali; James Dobson; Ivan Koludarov; Jordan Debono; Scott C Cutmore; Niwanthi W Rajapakse; Timothy N W Jackson; Rob Jones; Wayne C Hodgson; Bryan G Fry; Sanjaya Kuruppu
Journal:  Toxins (Basel)       Date:  2017-02-16       Impact factor: 4.546

Review 10.  Old World Vipers-A Review about Snake Venom Proteomics of Viperinae and Their Variations.

Authors:  Maik Damm; Benjamin-Florian Hempel; Roderich D Süssmuth
Journal:  Toxins (Basel)       Date:  2021-06-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.